DiaSorin S.p.A. shares declined 2.3% after the company revealed that Group Chief Financial Officer Piergiorgio Pedron will leave his post effective March 31, 2026 to take up the CFO role at payment company Nexi SpA.
The Milan-based diagnostics group confirmed that Alberto Donati will succeed Pedron, with the handover scheduled for April 1, 2026. Donati has been with DiaSorin for more than 14 years and, following DiaSorin's acquisition of Luminex in 2021, held the combined role of Group Controller and CFO of Luminex.
Donati's internal promotion comes as DiaSorin continues to place strategic emphasis on growing its molecular diagnostics operations. His background at the company includes financial leadership responsibilities across DiaSorin's China and Australia activities, as well as direct involvement in the integration of Luminex after the 2021 deal.
Market analysts at Morgan Stanley commented on the appointment, noting: "We understand that the appointment of Mr Donati aligns with the ambition for the Luminex/Molecular business to be a key driver of DiaSorin’s mid-term growth targets, in particular the execution of ongoing Molecular launches such as the LiaisonPlex and Liaison NES."
The share price movement indicates that investors are reacting to the change in the company's finance leadership. DiaSorin has been working to expand its molecular testing portfolio following the Luminex acquisition, and the promotion of a finance executive with hands-on experience in that part of the business signals continuity in prioritizing those initiatives.
Donati's elevation is notable for its internal continuity and direct relevance to the business unit highlighted by analysts as central to mid-term growth plans. The transition timeline gives the company a clear, immediate replacement, while the market response shows investor attention to governance and the potential implications for DiaSorin's execution of its molecular product launches.
Sectors impacted: Healthcare diagnostics, molecular diagnostics, and financial markets reacting to corporate leadership changes.